金刚烷胺预防由 SARS-CoV-2 引起的临床症状。
Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.
机构信息
Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Universidad Veracruzana/Instituto de Investigaciones Cerebrales, Xalapa, Veracruz, Mexico.
出版信息
Pharmacol Rep. 2021 Jun;73(3):962-965. doi: 10.1007/s43440-021-00231-5. Epub 2021 Feb 18.
Abstract
BACKGROUND
Amantadine is a drug that can help in the prevention of SARS-CoV-2 symptomatology, as has been demonstrated in observational clinical studies.
METHODS
We searched in the PubMed database Clinical Studies of coronavirus-infected patients who have been treated with amantadine in a preventive manner as well as patients with Parkinson's disease.
RESULTS
Four clinical studies were found in which relatives of patients with COVID-19 had been prescribed the use of amantadine in a preventive manner to avoid the symptoms caused by the coronavirus.
CONCLUSION
Amantadine is a drug that can be prescribed as a prophylactic that prevents symptomatology caused by SARS-CoV-2 coronavirus.
摘要
背景
金刚烷胺是一种可以帮助预防 SARS-CoV-2 症状的药物，这已经在观察性临床研究中得到证实。
方法
我们在 PubMed 数据库中搜索了接受金刚烷胺预防性治疗的冠状病毒感染患者以及帕金森病患者的临床研究。
结果
我们发现了四项临床研究，其中 COVID-19 患者的亲属被开处金刚烷胺用于预防，以避免冠状病毒引起的症状。
结论
金刚烷胺是一种可以作为预防药物来预防 SARS-CoV-2 冠状病毒引起的症状。
相似文献
1
Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.金刚烷胺预防由 SARS-CoV-2 引起的临床症状。
Pharmacol Rep. 2021 Jun;73(3):962-965. doi: 10.1007/s43440-021-00231-5. Epub 2021 Feb 18.
2
Amantadine Treatment for People with COVID-19.金刚烷胺治疗 COVID-19 患者。
Arch Med Res. 2020 Oct;51(7):739-740. doi: 10.1016/j.arcmed.2020.06.009. Epub 2020 Jun 12.
3
Observational study of people infected with SARS-Cov-2, treated with amantadine.对感染 SARS-CoV-2 并接受金刚烷胺治疗的人群进行的观察性研究。
Pharmacol Rep. 2020 Dec;72(6):1538-1541. doi: 10.1007/s43440-020-00168-1. Epub 2020 Oct 10.
4
Use of amantadine in a patient with SARS-CoV-2.金刚烷胺在一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者中的应用。
J Med Virol. 2021 Jan;93(1):110-111. doi: 10.1002/jmv.26179. Epub 2020 Jun 24.
5
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment.金刚烷胺破坏溶酶体基因表达：COVID19 治疗的一个假说。
Int J Antimicrob Agents. 2020 Jun;55(6):106004. doi: 10.1016/j.ijantimicag.2020.106004. Epub 2020 Apr 30.
6
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design.金刚烷胺在预防 SARS-CoV-2 病毒感染患者 COVID-19 症状进展和治疗中的应用（COV-PREVENT）：研究原理和设计。
Contemp Clin Trials. 2022 May;116:106755. doi: 10.1016/j.cct.2022.106755. Epub 2022 Apr 4.
7
Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro.离子通道抑制剂金刚烷胺、美金刚和金刚乙胺治疗 SARS-CoV-2 的体外疗效。
Viruses. 2021 Oct 15;13(10):2082. doi: 10.3390/v13102082.
8
Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention.氟伏沙明和金刚烷胺：重新定位用于 COVID-19 的中枢神经系统作用药物作为早期干预。
Curr Neuropharmacol. 2022;20(4):777-781. doi: 10.2174/1570159X19666210729123734.
9
Potential for the Repurposing of Adamantane Antivirals for COVID-19.金刚烷类抗病毒药物在新冠病毒中的再利用潜力。
Drugs R D. 2021 Sep;21(3):267-272. doi: 10.1007/s40268-021-00351-6. Epub 2021 Jun 21.
10
Amantadine as a drug to mitigate the effects of COVID-19.金刚烷胺作为一种减轻 COVID-19 影响的药物。
Med Hypotheses. 2020 Jul;140:109755. doi: 10.1016/j.mehy.2020.109755. Epub 2020 Apr 25.
引用本文的文献
1
COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine.2019冠状病毒病大流行浪潮以及2024 - 2025年冬季与血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂和金刚烷胺的关系
Healthcare (Basel). 2025 May 27;13(11):1270. doi: 10.3390/healthcare13111270.
2
NMDA receptor antagonists mitigate COVID-19-induced neuroinflammation and improve survival in a mouse model.N-甲基-D-天冬氨酸（NMDA）受体拮抗剂可减轻新型冠状病毒肺炎（COVID-19）诱导的神经炎症，并提高小鼠模型的存活率。
Sci Rep. 2025 Jun 4;15(1):19603. doi: 10.1038/s41598-025-00738-4.
3
COVID-19 in Relation to Chronic Antihistamine Prescription.与慢性抗组胺药处方相关的新型冠状病毒肺炎
Microorganisms. 2024 Dec 13;12(12):2589. doi: 10.3390/microorganisms12122589.
4
SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms.SARS-CoV-2 感染与α-突触核蛋白病：潜在关联及潜在机制。
Int J Mol Sci. 2024 Nov 10;25(22):12079. doi: 10.3390/ijms252212079.
5
COVID-19 in Relation to Polypharmacy and Immunization (2020-2024).COVID-19 与多药治疗和免疫接种（2020-2024 年）。
Viruses. 2024 Sep 27;16(10):1533. doi: 10.3390/v16101533.
6
Illicit COVID-19 products online: A mixed-method approach for identifying and preventing online health risks.非法的 COVID-19 产品在线：一种识别和预防在线健康风险的混合方法。
PLoS One. 2023 Jun 16;18(6):e0287231. doi: 10.1371/journal.pone.0287231. eCollection 2023.
7
COVID-19 and neurological disorders: what might connect Parkinson's disease to SARS-CoV-2 infection.新冠病毒与神经系统疾病：帕金森病与新冠病毒感染之间可能存在何种关联。
Front Neurol. 2023 May 18;14:1172416. doi: 10.3389/fneur.2023.1172416. eCollection 2023.
8
Do selected lifestyle parameters affect the severity and symptoms of COVID-19 among elderly patients? The retrospective evaluation of individuals from the STOP-COVID registry of the PoLoCOV study.选择的生活方式参数是否会影响老年患者 COVID-19 的严重程度和症状？来自 PoLoCOV 研究的 STOP-COVID 登记处的个体的回顾性评估。
J Infect Public Health. 2023 Jan;16(1):143-153. doi: 10.1016/j.jiph.2022.12.008. Epub 2022 Dec 12.
9
Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.肺部药物递送：抗击 COVID-19 的有效且便捷的给药途径。
Drug Deliv Transl Res. 2023 Mar;13(3):705-715. doi: 10.1007/s13346-022-01251-1. Epub 2022 Oct 19.
10
Treatment paradigms in Parkinson's Disease and Covid-19.帕金森病和新冠肺炎的治疗模式。
Int Rev Neurobiol. 2022;165:135-171. doi: 10.1016/bs.irn.2022.03.002. Epub 2022 May 28.
本文引用的文献
1
Docking Prediction of Amantadine in the Receptor Binding Domain of Spike Protein of SARS-CoV-2.金刚烷胺在新型冠状病毒刺突蛋白受体结合域中的对接预测
ACS Pharmacol Transl Sci. 2020 Nov 3;3(6):1430-1433. doi: 10.1021/acsptsci.0c00172. eCollection 2020 Dec 11.
2
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.瑞德西韦在人多能干细胞衍生的心肌细胞中抗 SARS-CoV-2 感染的抗病毒活性和安全性。
Antiviral Res. 2020 Dec;184:104955. doi: 10.1016/j.antiviral.2020.104955. Epub 2020 Oct 19.
3
Observational study of people infected with SARS-Cov-2, treated with amantadine.对感染 SARS-CoV-2 并接受金刚烷胺治疗的人群进行的观察性研究。
Pharmacol Rep. 2020 Dec;72(6):1538-1541. doi: 10.1007/s43440-020-00168-1. Epub 2020 Oct 10.
4
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
5
Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseases.具有刚性金刚烷骨架的天然和合成化合物的药理学特性，作为治疗神经退行性疾病的潜在药物。
Biochem Biophys Res Commun. 2020 Sep 3;529(4):1225-1241. doi: 10.1016/j.bbrc.2020.06.123. Epub 2020 Aug 7.
6
Amantadine, COVID-19 and Parkinsonism.金刚烷胺、新冠病毒肺炎与帕金森症
Arch Med Res. 2020 Oct;51(7):714. doi: 10.1016/j.arcmed.2020.07.001. Epub 2020 Jul 3.
7
Amantadine Treatment for People with COVID-19.金刚烷胺治疗 COVID-19 患者。
Arch Med Res. 2020 Oct;51(7):739-740. doi: 10.1016/j.arcmed.2020.06.009. Epub 2020 Jun 12.
8
Coronavirus breakthrough: dexamethasone is first drug shown to save lives.冠状病毒研究突破：地塞米松是首个被证明能挽救生命的药物。
Nature. 2020 Jun;582(7813):469. doi: 10.1038/d41586-020-01824-5.
9
Use of amantadine in a patient with SARS-CoV-2.金刚烷胺在一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者中的应用。
J Med Virol. 2021 Jan;93(1):110-111. doi: 10.1002/jmv.26179. Epub 2020 Jun 24.
10
Does amantadine have a protective effect against COVID-19?金刚烷胺对2019冠状病毒病有保护作用吗？
Neurol Neurochir Pol. 2020;54(3):284-285. doi: 10.5603/PJNNS.a2020.0041. Epub 2020 Jun 4.
Zotero 插件